Health Care

BIO opposes cloning to create a new human being (reproductive cloning) because it is unsafe and unethical. However, it is important to distinguish between that and other appropriate and important uses of the technology such as cloning specific human cells, genes and other tissues that do not and cannot lead to a human being (therapeutic cloning).

The Brownback Bill (S. 1899) is Bad for American Science and Medical Progress

The public has a strong interest in protecting research and research participants. Federal policy must find the right balance in protecting participants while allowing critical research to continue.

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

Every 70 seconds someone develops Alzheimer's. By 2029 there will be 70 million retired baby boomers. If we dont find a way to treat the disease we are going to have a public health disaster.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

Ohio is a national leader in terms of both bioscience employment and establishments. In fact the industry accounts for about 15 percent of the state’s total economic output.

Biotechnology might seem like a new science to many, but it has its roots in the work of some early big thinkers — among them George Washington Carver, arguably one of the world’s first industrial biotechnologists and the father of sustainable farming.

Scientific discoveries happen when researchers collaborate. That’s the thinking behind a partnership formed by GlaxoSmithKline and Alnylam Pharmaceuticals to share intellectual property (IP) and industrial know-how to develop new therapies to treat the world’s most neglected tropical diseases.

On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS).

Human organ transplantation is a relatively new field of medicine that is now facing a significant challenge.

March 14 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the "Proposed Rule: Supplemental Applications Proposing Labelling Changes for Approved Drugs and Biological Products."
March 10 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments to the docket regarding “Complex Issues in Developing Drug and Biologics Products for Rare Diseases.” Comments are being provided in two areas; general comments on the challenges of rare disease drug development, and specific comments in response to the public workshop.
March 4 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Request for Nominations: Drug Products that Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.”
February 3 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act.”
January 31 2014
The Biotechnology Industry Organization (BIO) respectfully submits these comments in response to the Generic Pharmaceutical Association (GPhA) Citizen Petition requesting the Food and Drug Administration (FDA) to “implement its INN naming policy equally to all biologics” and to require “all biologics approved under the Section 351(k) pathway…share the same INN [International Nonproprietary Name] as the RPP [reference protein product]” (the GPhA Petition).
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed